Modern treatment of metastatic prostate cancer

Henriette Veiby Holm; Alv A Dahl; Olbjørn Harald Klepp; Sophie D Fosså

doi:10.4045/tidsskr.16.0265

Modern treatment of metastatic prostate cancer

Tidsskr Nor Laegeforen. 2017 Jun 6;137(11):803-805. doi: 10.4045/tidsskr.16.0265. eCollection 2017 Jun.

[Article in English, Norwegian]

Authors

Henriette Veiby Holm¹, Alv A Dahl², Olbjørn Harald Klepp³, Sophie D Fosså²

Affiliations

¹ Kirurgisk avdeling Bærum sykehus.
² Nasjonalt kompetansesenter for seneffekter etter kreftbehandling Oslo universitetssykehus, Radiumhospitalet.
³ Kreftavdelingen Helse Møre og Romsdal.

PMID: 28597635
DOI: 10.4045/tidsskr.16.0265

Abstract

The treatment of prostate cancer with remote metastases has advanced greatly in recent years. Treatment options are dependent on the extent of the metastases, the patient’s general condition and wishes, and the treatment response. We present an overview of the latest options for systemic treatment of patients with metastatic prostate cancer, based on availability in Norway.

Publication types

Review

MeSH terms

Algorithms
Androgen Antagonists / therapeutic use
Antineoplastic Agents / therapeutic use
Humans
Male
Neoplasm Metastasis / drug therapy
Norway
Orchiectomy
Prostate-Specific Antigen / blood
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / pathology
Prostatic Neoplasms* / radiotherapy
Prostatic Neoplasms* / surgery
Prostatic Neoplasms, Castration-Resistant / drug therapy
Prostatic Neoplasms, Castration-Resistant / pathology
Prostatic Neoplasms, Castration-Resistant / radiotherapy
Prostatic Neoplasms, Castration-Resistant / surgery

Substances

Androgen Antagonists
Antineoplastic Agents
Prostate-Specific Antigen